SciSparc Ltd. (NASDAQ:SPRC) Sees Significant Drop in Short Interest

SciSparc Ltd. (NASDAQ:SPRC) saw a significant decline in short interest in the month of February. As of February 13th, there was short interest totaling 138,165 shares, a decline of 21.5% from the January 29th total of 176,031 shares. Based on an average daily volume of 171,035 shares, the short-interest ratio is presently 0.8 days. Currently, 3.9% of the company’s shares are sold short. Currently, 3.9% of the company’s shares are sold short. Based on an average daily volume of 171,035 shares, the short-interest ratio is presently 0.8 days.

SciSparc Stock Performance

Shares of NASDAQ SPRC opened at $4.76 on Wednesday. The company has a 50 day simple moving average of $0.94 and a 200-day simple moving average of $2.36. SciSparc has a 1 year low of $0.46 and a 1 year high of $10.82.

SciSparc (NASDAQ:SPRC) last released its quarterly earnings data on Tuesday, November 18th. The company reported ($27.73) EPS for the quarter. The company had revenue of $0.23 million during the quarter.

SciSparc Company Profile

SciSparc AG is a clinical‐stage medical technology company focused on the development and commercialization of extracorporeal shock wave–based neuromodulation devices. Founded in 2016 and headquartered in Switzerland, the company applies proprietary low‐intensity shock wave technology to noninvasively stimulate neural tissue. SciSparc completed its initial public offering on the NASDAQ in 2021 under the ticker SPRC, securing funding to advance its clinical pipeline.

The company’s lead product, the TR100 system, delivers transcranial shock wave stimulation (tSWS) designed to target areas of the brain associated with motor control and cognitive function.